Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 32, Number 4—April 2026

Research

Confirming ERVEBO Vaccination to Support Ebola Virus Surveillance

Elif Karaaslan, Amy Whitesell, Jason Malenfant, William C. Carson, Michael Townsend, Kasongo Kayembe Jolie, Enogo Koivogui, Siba Michel Grovogui, Boubacar Diallo, Nouonan Gbamou, Salomon Corvil, Sanaba Boumbaly, Lise Martel, Julie R. Sinclair, Alimou Camara, Trevor Shoemaker, Mary J. Choi, Joel M. Montgomery, Christina F. Spiropoulou, and Éric BergeronComments to Author 
Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E. Karaaslan, A. Whitesell, J. Malenfant, W.C. Carson, M. Townsend, L. Martel, J.R. Sinclair, T. Shoemaker, M.J. Choi, J.M. Montgomery, C.T. Spiropoulou, É. Bergeron); African Field Epidemiology Network, Conakry, Guinea (K.K. Jolie, S. Corvil); Ministry of Health, Conakry (E. Koivogui, S.M. Grovogui); US Centers for Disease Control and Prevention, Conakry (B. Diallo); Agence Nationale de Sécurité Sanitaire, Conakry (N. Gbamou); International Center for Research of Tropical Infections in Guinea, N’Zerekore, Guinea (S. Boumbaly); Ministry of Higher Education, Scientific Research, and Innovation, Conakry (A. Camara); University of Georgia, Athens, Georgia, USA (É. Bergeron).

Main Article

Figure 4

Superiority of EBOV sGP and VSV-P-N in identifying ERVEBO vaccinees for study of development of multiplex assay to confirm Ebola vaccination. A) Percentages of persons with vaccination cards (n = 115) whose vaccination status was confirmed by either positive VSV-P-N and EBOV sGP or positive VSV-P-N and EBOV GP1,2. B, C) Correlation of VSV-P-N and EBOV sGP (B) and VSV-P-N and EBOV GP1,2 (C). D) Percentages of persons with verbally confirmed vaccination status (n = 411) that were confirmed as vaccinees on the basis of positivity for either VSV-P-N and EBOV sGP, or VSV-P-N and EBOV GP1,2. E, F) Correlation of VSV-P-N and EBOV sGP (E) and VSV-P-N and EBOV GP1,2 (F). Error bars indicate 95% CIs. Correlations between results were tested by Spearman correlation r values with 95% CIs. Horizontal and vertical lines in the scatter plots indicate the established cutoff values for the antigens shown on the corresponding axes. Each quadrant of the correlation graphs is labeled with the percentage of the samples that tested negative, single positive, and double positive by assays given on the x- and y-axes. Figure created using BioRender (https://www.biorender.com). EBOV, Ebola virus; GP, glycoprotein; sGP, secreted glycoprotein; VSV-P-N, vesicular stomatitis virus nucleoprotein N-terminally fused with P peptide.

Figure 4. Superiority of EBOV sGP and VSV-P-N in identifying ERVEBO vaccinees for study of development of multiplex assay to confirm Ebola vaccination. A) Percentages of persons with vaccination cards (n = 115) whose vaccination status was confirmed by either positive VSV-P-N and EBOV sGP or positive VSV-P-N and EBOV GP1,2. B, C) Correlation of VSV-P-N and EBOV sGP (B) and VSV-P-N and EBOV GP1,2 (C). D) Percentages of persons with verbally confirmed vaccination status (n = 411) that were confirmed as vaccinees on the basis of positivity for either VSV-P-N and EBOV sGP, or VSV-P-N and EBOV GP1,2. E, F) Correlation of VSV-P-N and EBOV sGP (E) and VSV-P-N and EBOV GP1,2 (F). Error bars indicate 95% CIs. Correlations between results were tested by Spearman correlation r values with 95% CIs. Horizontal and vertical lines in the scatter plots indicate the established cutoff values for the antigens shown on the corresponding axes. Each quadrant of the correlation graphs is labeled with the percentage of the samples that tested negative, single positive, and double positive by assays given on the x- and y-axes. Figure created using BioRender (https://www.biorender.com). EBOV, Ebola virus; GP, glycoprotein; sGP, secreted glycoprotein; VSV-P-N, vesicular stomatitis virus nucleoprotein N-terminally fused with P peptide.

Main Article

Page created: March 04, 2026
Page updated: March 30, 2026
Page reviewed: March 30, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external